Agios keeps U.S. rights to a top drug in Celgene pact; Regado raising $20M;

@FierceBiotech: Buzz: GlaxoSmithKline prepares to unveil a new PhIII lineup. Story | Follow @FierceBiotech

@JohnCFierce: Eager biotechs (9!) crowd into Wall Street this week with $500M in IPO pitches. News | Follow @JohnCFierce

@DamianFierce: Portola takes its 'breakthrough' bleeding drug to PhIII with Bayer, J&J in tow. Read | Follow @DamianFierce

@EmilyMFierce: Merck halts drug testing on chimpanzees. Story | Follow @EmilyMFierce

> Agios Pharmaceuticals ($AGIO) says it is hanging on to the U.S. commercialization rights to AG-120 and its isocitrate dehydrogenase 1 (IDH1) portfolio, part of a big pact the biotech struck with Celgene ($CELG). Celgene will take the development lead outside the U.S. Release

> Regado Biosciences ($RGDO) is raising $20 million in a private placement. Release

Medical Device News

@FierceMedDev: Montagu Private Equity grabs Rexam's healthcare packaging arm for $805M. Story | Follow @FierceMedDev

@MarkHFierce: ArthroCare, stained by a federal fraud scandal, gets a fresh start with Smith & Nephew's planned $1.7B acquisition. More | Follow @MarkHFierce

@MichaelGFierce: Study reports success in targeted therapy for common form of lung cancer. Report | Follow @MichaelGFierce

@EmilyWFierce: Given Imaging scores FDA seal of approval for PillCam COLON device. News | Follow @EmilyWFierce

> Neovasc makes a first-in-human implant of its transcatheter mitral valve. More

> Apple joins Google on FDA med tech regulators' meeting calendar. Story

Pharma News

@FiercePharma: WSJ: Scientist's lawsuit accuses AstraZeneca of fudging Brilinta study. Story | Follow @FiercePharma

@TracyStaton: Biogen Idec's Tecfidera nabs EU approval for first-line MS treatment. Rollout TK. More | Follow @TracyStaton

@EricPFierce: The FDA says it will take a look at the heart risks of testosterone boosting drugs. Report | Follow @EricPFierce

@CarlyHFierce: More Humira sales gains help AbbVie meet forecasts. News | Follow @CarlyHFierce

> WSJ: Scientist's lawsuit accuses AstraZeneca of fudging Brilinta study. More

> Suitors size up Merck's consumer unit for potential $10B deal: Reuters. Story

> Valeant adds to skin-care quiver with $475M PreCision Dermatology buy. News

CRO News

> Parexel rebounds from a shaky fall as sales jump 15%. Article

> Indian CRO GVK buys its way into biologics with Aragen deal. Story

> Ergomed cuts a risk-sharing deal on Ferrer's insomnia drug. News

> InVentiv looks to corner the market on mid-size biotechs. Story

> Growing Novotech makes its way into Africa. Article

> Algorithme doubles down on complex trials with latest addition. Brief

Biotech IT News

> J&J hands Yale the keys to its clinical trial data vault. Story

> Dassault makes a $750M play for Accelrys to expand into R&D software. Article

> Infosys co-founder backs an Indian brain computing center. News

> Bioinformatics skills help Stanford to a $40M genomics grant. Story

> The FDA's Mini-Sentinel healthcare surveillance database is growing quickly. Article

> Empiriko teams up to scale liver-mimicking technology. Brief

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.